|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12N 15/11 | |
| C12N 15/113 | |||
| A61K 47/54 | |||
| C07H 21/04 | |||
| C07H 1/00 | |||
| C07H 99/00 |
| (11) | Patento numeris | 3569711 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19180844.3 |
| Europos patento paraiškos padavimo data | 2015-12-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-11-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-02-03 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201462092241 P | 2014-12-15 | US | |
| 201462092238 P | 2014-12-15 | US | |
| 201562187856 P | 2015-07-02 | US | |
| 201562187848 P | 2015-07-02 | US |
| (72) |
BROWN, Bob, Dale, US
WANG, Weimin, US
|
| (73) |
Dicerna Pharmaceuticals, Inc.,
33, Hayden Avenue, Lexington, MA 02421,
US
|
| (54) | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS |
| LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS |